After release of Covaxin’s phase 3 efficacy data, NTAGI chief says it will help vaccine get WHO recognition \
2 min read
\
\

After release of Covaxin’s phase 3 efficacy data, NTAGI chief says it will help vaccine get WHO recognition

03-Jul-2021
New Delhi [India], (ANI): Hours after Bharat Biotech announced that its vaccine Covaxin's efficacy against COVID-19 is 77.8 per cent, National Technical Advisory Group on Immunisation (NTAGI) Chief Dr NK Arora said that these results will help the vaccine get recognition from the World Health Organisation (WHO).
03-Jul-2021 Coronavirus
\
Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chief \
4 min read
\
\

Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chief

27-Jun-2021
New Delhi [India], June 27 (ANI): Zydus Cadila COVID-19 vaccine for children above 12 years is expected to be available by August as its trials are likely to be completed by July-end, said Dr N K Arora, Chairman, National Technical Advisory Group on Immunisation (NTAGI).
27-Jun-2021 Coronavirus
\
Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chief \
4 min read
\
\

Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chief

27-Jun-2021
New Delhi [India], June 27 (ANI): Zydus Cadila COVID-19 vaccine for children above 12 years is expected to be available by August as its trials are likely to be completed by July-end, said Dr N K Arora, Chairman, National Technical Advisory Group on Immunisation (NTAGI).
27-Jun-2021 Coronavirus
\
There is no dissent on increasing gap between does of Covid-19 vaccine Covishield: NTAGI Member \
3 min read
\
\

There is no dissent on increasing gap between does of Covid-19 vaccine Covishield: NTAGI Member

16-Jun-2021
New Delhi [India], June 16 (ANI): Chairman of the National Technical Advisory Group on Immunisation (NTAGI) on Wednesday refuted reports that there was dissent among experts within the scientific group about extending the does intervals of the Covid-19 vaccine Covishield to 12 to 16 weeks and that the Centre had taken the decision to do so without their agreement.
16-Jun-2021 Coronavirus
\
Decision to increase gap between Covishield doses based on scientific evidence: NTAGI Chairman \
5 min read
\
\

Decision to increase gap between Covishield doses based on scientific evidence: NTAGI Chairman

16-Jun-2021
New Delhi [India], June 16 (ANI): Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora on Wednesday stated that the decision to increase the gap between two Covishield doses from 4-6 weeks to 12-16 weeks is based on "fundamental scientific reasons".
16-Jun-2021 Coronavirus
\
Covishield COVID-19 Vaccine Dosage Gap Increase Decision Taken Based on Scientific Evidence, Says NTAGI Chairman Dr NK Arora \
8 min read
\
\

Covishield COVID-19 Vaccine Dosage Gap Increase Decision Taken Based on Scientific Evidence, Says NTAGI Chairman Dr NK Arora

16-Jun-2021
Dr N K Arora explained that the decision to increase the gap between two COVISHIELD doses from 4-6 weeks to 12 - 16 weeks lay in the fundamental scientific reason regarding behaviour of adenovector vaccines.
16-Jun-2021 Coronavirus
\